Start free

PolicyChanges tracks payer policy changes for medical practices and tells you what to do before they take effect.

Create a free accountPolicy Monitoring is free. No card required.
← Back to list
Blue Cross & Blue Shield of MississippiCommercial · Coverage · Medical Policy · Oncology, GeneticsMedium impact

Laboratory and Genetic Testing for Use of 5-Fluorouracil in Patients With Cancer

Effective date
Not stated in the notice
Identified
Jun 20, 2026

Summary

Under this BCBS policy, assay testing for 5-fluorouracil area under the curve to adjust 5-fluorouracil dose for individuals with cancer is considered investigational. Genetic testing for DPYD or TYMS variants to guide 5-fluorouracil dosing or treatment choice in individuals with cancer is also considered investigational. The policy history records 04/17/2025 and 04/18/2024 reviews with no changes.

Get alerts when payers change rules like this one

We check Blue Cross & Blue Shield of Mississippi and other payers every day and email you when a change matches your specialty and state.

Get Blue Cross & Blue Shield of Mississippi alertsPolicy Monitoring is free. No card required.

What to do

Action · 3 steps
01Billing team: Assay testing for 5-fluorouracil area under the curve to adjust dose, and genetic testing for DPYD or TYMS variants to guide 5-fluorouracil dosing or treatment choice, are considered investigational under this policy.
02The code reference lists CPT 81232, CPT 81346, CPT 84999 and HCPCS S3722 as investigational codes.
03Check the member's specific benefit plan language, since the Medical Policy Manual guidelines should not be used in place of it.

Codes mentioned

812328134684999S3722

Original notice

Laboratory and Genetic Testing for Use of 5-Fluorouracil in Patients With Cancer
bcbsms.com · Always check the source before changing claims.
View original ↗

Related changes

See all Blue Cross & Blue Shield of Mississippi changes →
Somatic Biomarker Testing (Including Liquid Biopsy) for Targeted Treatment in Non-Small-Cell Lung Cancer (EGFR, ALK, BRAF, ROS1, RET, MET, KRAS, NTRK)MediumNo effective date · Medical PolicyIntracellular Micronutrient AnalysisMediumNo effective date · Medical PolicyGermline Genetic Testing for Familial Cutaneous Malignant Melanoma (CDKN2A, CDK4)MediumNo effective date · Medical PolicyMolecular Genomic Profiling for Cancers of Unknown PrimaryMediumNo effective date · Medical PolicyBrowse every Blue Cross & Blue Shield of Mississippi change in the policy list

Related policy hubs

Blue Cross & Blue Shield of Mississippi policiesOncologyGeneticsCode 81232Code 81346Code 84999Code S3722

Summaries are AI-assisted. Always confirm against the original payer notice.

What is PolicyChanges

One workspace for payer rules, prior auth, coding and compliance

Medical practices use PolicyChanges to catch payer changes before they cause denials. Every change is summarized in plain English, with the codes involved, the date it takes effect and what to do.

Policy MonitoringPayer policy, prior auth and coding changes, filtered to your saved searchesOIG ScreeningStaff and vendors screened every month against OIG LEIE, SAM.gov and state Medicaid listsPrior Auth LookupKnow if a service needs prior authorization before you schedule itCredentialing TrackerLicenses, CAQH, Medicare revalidation and payer enrollments, with reminders before anything lapsesCompliance CenterKeep your HIPAA program documented and ready to show
Start freePolicy Monitoring is free. No card required.
Get alerts for changes like thisPolicy Monitoring is free. No card required.Create a free account